For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- UMN to Open Japan’s Biggest Biopharmaceutical Contract Manufacturing Facility; Success or Failure Could Determine the Future of this Business in Japan
April 30, 2013
- Ethical Drug Production to Exceed 12 Trillion Yen in 2020: Yano Research Institute
April 30, 2013
- Sandoz K.K. Applies for Gran Biosimilar
April 26, 2013
- Daiichi Sankyo Begins Nimotuzumab PIII Trials for Lung and Gastric Cancers
April 26, 2013
- Boehringer Filed NDA for Afatinib in Japan: Chairman
April 26, 2013
- Takeda Files NDA for Fixed-Dose Combination of Azilva/Amlodipine in Japan
April 26, 2013
- Edoxaban Will Be Key to Achieving Targets in Daiichi Sankyo’s New 5-Year Business Plan
April 26, 2013
- Takeda Initiates Voluntary Partial Recall for Azilva due to Incorrect Expiry Date on Packaging Carton
April 25, 2013
- GSK Files NDA for LAMA/LABA Combination Drug for COPD Treatment
April 24, 2013
- Shionogi Revises Profit Forecasts for FY2012
April 24, 2013
- AnGes MG’s CIN Therapeutic Vaccine Demonstrates Increased Efficacy in Combination with Kampo Medicine
April 24, 2013
- Merck Serono to Launch New Gonalef Pen Devices Starting in May
April 24, 2013
- Ibandronate Injection Non-Inferior to Risedronate: Chugai, Taisho
April 23, 2013
- Nichi-Iko to Launch Allegra AG in June, Says Identical with Original
April 23, 2013
- Daiichi Sankyo Launches Silodosin in China
April 23, 2013
- Ono Pharmaceutical Obtains Exclusive Rights for Once-Daily Wearing-Off Treatment
April 22, 2013
- Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
- Taisho Files SGLT-2 Inhibitor Luseogliflozin, Submits RMP
April 22, 2013
- Merck Serono Obtains Marketing Rights for Cetrotide from Shionogi
April 22, 2013
- AnGes MG, Shionogi to Start PI Study for Nucleic Acid Drug for Atopic Dermatitis
April 19, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…